Adc therapeutics sa ADCT.US 總覽分析
)ADCT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
ADCT 近期報酬表現
5.51%
Adc therapeutics sa
4.57%
同產業平均
3.26%
S&P500
與 ADCT 同產業的標的表現
- BIOA Bioage labs inc價值 -趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
ADCT 公司資訊
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin's lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.